• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Aurinia reports favourable assessment of LUPKYNIS in ICER pharmaceutical-technology
    March 18, 2021
    Aurinia Pharmaceuticals (IPHAF) has announced a positive cost-effectiveness assessment of LUPKYNIS (voclosporin) based on the Institute for Clinical and Economic Review (ICER) revised evidence report analysis.
  • Catalent, Aurinia Ink LUPKYNIS Commercial Supply Pact contractpharma
    February 20, 2021
    Catalent has signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals for LUPKYNIS (voclosporin), a drug to treat adult patients with lupus nephritis (LN).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service